You are viewing this article in the archives. For the latest breaking news and updates in Ann Arbor and the surrounding area, see
Posted on Tue, Mar 15, 2011 : 8:24 a.m.

Report: University of Michigan-led ALS stem cell trial moves forward

By Juliana Keeping

A University of Michigan-led clinical stem cell trial for Lou Gehrig’s disease is poised to take an important step forward.


Eva Feldman

Photo courtesy of the University of Michigan

The trial, led by University of Michigan neurologist Eva Feldman, has been evaluating the safety of injecting millions of stem cells into patients’ spines, The Detroit News reports. Next, the trial will begin testing the safety of the procedure in the part of the spine that could save lives, according to The News.

Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease or ALS, is a neurological condition that robs its victims of their ability to speak, move and eventually breathe, while leaving their minds alert. Roughly 30,000 Americans are afflicted with the disease and 5,600 diagnosed each year, according to the ALS Association.

The study is being conducted at the Neuromuscular Laboratory at Emory University in Atlanta with Feldman on board as a consultant to Neuralstem Inc., the trial’s sponsor.

Juliana Keeping is a health and environment reporter for Reach her at or 734-623-2528. Follow Juliana Keeping on Twitter



Tue, Mar 15, 2011 : 2:37 p.m.

Bravo Dr. Feldman! I hope these trials have a positive outcome. My mother was an MD who had ALS for 8 years - it's a terrible, terrible disease with no real treatments beyond trying to make the patient more comfortable. Thank you for you and your team's hard work!